The HIV epidemic: High-income countries

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 5, 2012, Pages

  Vermund, Sten H ^a   Leigh Brown, Andrew J ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; EPIDEMIC; GENE SEQUENCE; GENETIC VARIABILITY; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INCOME; MEN WHO HAVE SEX WITH MEN; PREVALENCE; VIRUS LOAD; ANTIVIRAL RESISTANCE; BLOOD TRANSFUSION; DEVELOPED COUNTRY; DRINKING BEHAVIOR; DRUG ABUSE; ECONOMICS; FEMALE; MALE; MALE HOMOSEXUALITY; MOLECULAR EPIDEMIOLOGY; REVIEW; RISK FACTOR; STATISTICS; SUBSTANCE ABUSE; UNSAFE SEX; VERTICAL TRANSMISSION;

ALCOHOL DRINKING; BLOOD TRANSFUSION; DEVELOPED COUNTRIES; DRUG RESISTANCE, VIRAL; EPIDEMICS; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INCOME; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOLECULAR EPIDEMIOLOGY; NEEDLE SHARING; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNSAFE SEX;

EID: 84869202927     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a007195     Document Type: Article

References (247)

1. Abecasis AB, Lemey P, Vidal N, de Oliveira T, Peeters M, Camacho R, Shapiro B, Rambaut A, Vandamme AM. 2007. Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: Subtype G is a circulating recombinant form. J Virol 81: 8543-8551.
2. Aceijas C, Stimson GV, Hickman M, Rhodes T. 2004. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18: 2295-2303.
3. Aceijas C, Hickman M, Donoghoe MC, Burrows D, Stuikyte R. 2007. Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction 102: 1244-1250.
4. Adimora AA, Schoenbach VJ, Floris-Moore MA. 2009. Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med 37: 468-471.
5. Alizon M, Wain-Hobson S, Montagnier L, Sonigo P. 1986. Genetic variability of the AIDS virus: Nucleotide sequence analysis of two isolates from African patients. Cell 46: 63-74.
6. Anderson JP, Rodrigo AG, Learn GH, Madan A, Delahunty C, Coon M, Girard M, Osmanov S, Hood L, Mullins JI. 2000. Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E. J Virol 74: 10752-10765.
7. Arnold C, Barlow KL, Parry JV, Clewley JP. 1995. At least five HIV-1 sequence subtypes (A, B, C, D, A/E) occur in England. AIDS Res Hum Retroviruses 11: 427-429.
8. AuBuchon JP, Birkmeyer JD, Busch MP. 1997. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 37: 45-51.
9. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. 2005. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med 2: e298. doi: 10. 1371/journal. pmed. 0020298.
10. Baggaley RF, White RG, Boily MC. 2010. HIV transmission risk through anal intercourse: Systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 39: 1048-1063.
11. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. 2007. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 369: 643-656.
12. Balfe P, Simmonds P, Ludlam CA, Bishop JO, Brown AJ. 1990. Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: Rate of sequence change and low frequency of inactivating mutations. J Virol 64: 6221-6233.
13. Baral S, Sifakis F, Cleghorn F, Beyrer C. 2007. Elevated risk for HIV infection among men who have sex with men in low-and middle-income countries 2000-2006: A systematic review. PLoS Med 4: e339. doi: 10. 1371/journal. pmed. 0040339.
14. Barrow RY, Berkel C, Brooks LC, Groseclose SL, Johnson DB, Valentine JA. 2008. Traditional sexually transmitted disease prevention and control strategies: Tailoring for African American communities. Sex Transm Dis 35: S30-S39.
15. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. 2010. Hepatitis B/C and HIV in sub-Saharan Africa: An association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 14: e1024-e1031.
16. + T lymphocyte death: Relevance to HIV and HCV pathogenesis. Front Biosci 7: d1689-d1696.
17. Birkhead GS, Pulver WP, Warren BL, Hackel S, Rodriguez D, Smith L. 2010. Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002-2006. Obstet Gynecol 115: 1247-1255.
18. Bobashev GV, Zule WA. Modeling the effect of high dead-space syringes on the human immunodeficiency virus (HIV) epidemic among injecting drug users. 2010. Addiction 105: 1439-1447.
19. Bobkov A, Cheingsong-Popov R, Garaev M, Rzhaninova A, Kaleebu P, BeddowsS, Bachmann MH, Mullins JI, Louwagie J, Janssens W, et al. 1994. Identification of an env G subtype and heterogeneity of HIV-1 strains in the Russian Federation and Belarus. AIDS 8: 1649-1655.
20. Bobkov A, Cheingsong-Popov R, Selimova L, Ladnaya N, Kazennova E, Kravchenko A, Fedotov E, Saukhat S, Zverev S, Pokrovsky V, et al. 1997. An HIV type 1 epidemic among injecting drug users in the former Soviet Union caused by a homogeneous subtype A strain. AIDS Res Hum Retroviruses 13: 1195-1201.
21. Bobkov A, Kazennova E, Khanina T, Bobkova M, Selimova L, Kravchenko A, Pokrovsky V, Weber J. 2001. An HIV type 1 subtype A strain of low genetic diversity continues to spread among injecting drug users in Russia: Study of the new local outbreaks in Moscow and Irkutsk. AIDS Res Hum Retroviruses 17: 257-261.
22. Bobkov AF, Kazennova EV, Sukhanova AL, Bobkova MR, Pokrovsky VV, ZemanVV, Kovtunenko NG, Erasilova IB. 2004. An HIV type 1 subtype A outbreak among injecting drug users in Kazakhstan. AIDS Res Hum Retroviruses 20: 1134-1136.
23. Bobrova N, Rughnikov U, Neifeld E, Rhodes T, Alcorn R, Kirichenko S, Power R. 2008. Challenges in providing drug user treatment services in Russia: Providers' views. Subst Use Misuse 43: 1770-1784.
24. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M. 2009. Heterosexual risk of HIV-1 infection per sexual act: Systematic review and meta-analysis of observational studies. Lancet Infect Dis 9: 118-129.
25. Bongaarts J, Reining P, Way P, Conant F. 1989. The relationship between male circumcision and HIV infection in African populations. AIDS 3: 373-377.
26. Booth RE, Kwiatkowski CF, Brewster JT, Sinitsyna L, Dvoryak S. 2006. Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS20: 2217-2223.
27. Booth RE, Lehman WE, Kwiatkowski CF, Brewster JT, Sinitsyna L, Dvoryak S. 2008. Stimulant injectors in Ukraine: The next wave of the epidemic? AIDS Behav 12: 652-661.
28. Brenchley JM, Douek DC. 2008. HIV infection and the gastrointestinal immune system. Mucosal Immunol 1: 23-30.
29. Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, RoutyJP, Wainberg MA. 2008. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 22: 2509-2515.
30. Buchbinder S. 2009. The epidemiology of new HIV infections and interventions to limit HIV transmission. Top HIV Med 17: 37-43.
31. Burchell AN, Calzavara LM, Orekhovsky V, Ladnaya NN. 2008. Characterization of an emerging heterosexual HIV epidemic in Russia. Sex Transm Dis 35: 807-813.
32. Burns DN, Dieffenbach CW, Vermund SH. 2010. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 51: 725-731.
33. Burrows D. 1998. Injecting equipment provision in Australia: The state of play. Subst Use Misuse 33: 1113-1127.
34. Busch MP, Dodd RY, Lackritz EM, AuBuchon JP, Birkmeyer JD, Petersen LR. 1997. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group. Transfusion 37: 1003-1011.
35. Cabral GA. 2006. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 1: 280-295.
36. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, et al. 2005. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ 331: 1368.
37. Carrington M, Alter G. 2011. Innate immune control of HIV disease. Cold Spring Harbor Perspect Med doi: 10. 1101/cshperspect. a007070.
38. Centers for Disease Control. 1981. Kaposi's sarcoma and Pneumocystispneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 30: 305-308.
39. Centers for Disease Control. 1982. Update on acquired immune deficiency syndrome (AIDS)-United States. MMWR Morb Mortal Wkly Rep 31: 507-508, 513-504.
40. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, et al. 2009. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 23: 717-724.
41. Chesney MA, Koblin BA, Barresi PJ, Husnik MJ, Celum CL, Colfax G, Mayer K, McKirnan D, Judson FN, Huang Y, et al. 2003. An individually tailored intervention for HIV prevention: Baseline data from the EXPLORE Study. Am J Public Health 93: 933-938.
42. Cohen MS, Gay CL, Busch MP, Hecht FM. 2010. The detection of acute HIV infection. J Infect Dis 202 Suppl 2: S270-S277.
43. Cohen MS, Haynes BF, McMichael AJ, Shaw GM. 2011. Medical Progress: Acute HIV-1 infection. N Engl J Med 364: 1943-1954.
44. Colfax G, Vittinghoff E, Husnik MJ, McKirnan D, Buchbinder S, Koblin B, CelumC, Chesney M, Huang Y, Mayer K, et al. 2004. Substance use and sexual risk: A participant-and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol 159: 1002-1012.
45. Colfax G, Coates TJ, Husnik MJ, Huang Y, Buchbinder S, Koblin B, Chesney M, Vittinghoff E. 2005. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. J Urban Health 82: 62-70.
46. Collins C, Harshbarger C, Sawyer R, Hamdallah M. 2006. The diffusion of effective behavioral interventions project: Development, implementation, and lessons learned. AIDS Educ Prev 18: 5-20.
47. Committee on Pediatric AIDS. 2008. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics 122: 1127-1134.
48. Corsi KF, Booth RE. 2008. HIV sex risk behaviors among heterosexual methamphetamine users: Literature review from 2000 to present. Curr Drug Abuse Rev 1: 292-296.
49. Coutinho RA, van Griensven GJ, Moss A. 1989. Effects of preventive efforts among homosexual men. AIDS 3 Suppl 1: S53-S56.
50. Crandall KA, Vasco DA, Posada D, Imamichi H. 1999. Advances in understanding the evolution of HIV. AIDS 13 Suppl A: S39-S47.
51. Crawford ND, Vlahov D. 2010. Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr 55Suppl 2: S84-S87.
52. Dandekar S. 2007. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 4: 10-15.
53. De Cock KM, Brun-Vezinet F. 1989. Epidemiology of HIV-2 infection. AIDS 3Suppl 1: S89-S95.
54. DeGruttola V, Smith DM, Little SJ, Miller V. 2010. Developing and evaluating comprehensive HIV infection control strategies: Issues and challenges. Clin Infect Dis 50 Suppl 3: S102-S107.
55. Dehne KL, Khodakevich L, Hamers FF, Schwartlander B. 1999. The HIV/AIDS epidemic in eastern Europe: Recent patterns and trends and their implications for policy-making. AIDS 13: 741-749.
56. Des Jarlais DC. 2000. Research, politics, and needle exchange. Am J Public Health 90: 1392-1394.
57. de Oliveira T, Pillay D, Gifford RJ. 2010. The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One 5: e9311. doi: 10. 1371/journal. pone. 0009311.
58. de Ronde A, Schuurman R, Goudsmit J, van den Hoek A, Boucher C. 1996. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands. AIDS 10: 231-232.
59. Di Lorenzo G. 2008. Update on classic Kaposi sarcoma therapy: New look at an old disease. Crit Rev Oncol Hematol 68: 242-249.
60. Doherty IA. 2011. Sexual networks and sexually transmitted infections: Innovations and findings. Curr Opin Infect Dis 24: 70-77.
61. Downing M, Riess TH, Vernon K, Mulia N, Hollinquest M, McKnight C, JarlaisDC, Edlin BR. 2005. What's community got to do with it? Implementation models of syringe exchange programs. AIDS Educ Prev 17: 68-78.
62. Drucker E, Lurie P, Wodak A, Alcabes P. 1998. Measuring harm reduction: The effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS 12 Suppl A: S217-S230.
63. Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 7: 214.
64. Dworkin SL, Ehrhardt AA. 2007. Going beyond "ABC" to include "GEM": Critical reflections on progress in the HIV/AIDS epidemic. Am J Public Health 97: 13-18.
65. Dwyre DM, Fernando LP, Holland PV. 2011. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 100: 92-98.
66. Ekanem EE, Afolabi BM, Nuga AO, Adebajo SB. 2005. Sexual behaviour, HIV-related knowledge and condom use by intra-city commercial bus drivers and motor park attendants in Lagos, Nigeria. Afr J Reprod Health 9: 78-87.
67. Ekwueme DU, Weniger BG, Chen RT. 2002. Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull World Health Organ 80: 859-870.
68. El-Bassel N, Gilbert L, Witte S, Wu E, Hunt T, Remien RH. 2010. Couple-based HIV prevention in the United States: Advantages, gaps, and future directions. J Acquir Immune Defic Syndr 55 Suppl 2: S98-S101.
69. Elovich R, Drucker E. 2008. On drug treatment and social control: Russian narcology's great leap backwards. Harm Reduct J 5: 23.
70. El-Sadr WM, Mayer KH, Hodder SL. 2010. AIDS in America-Forgotten but not gone. N Engl J Med 362: 967-970.
71. Evatt BL, Gomperts ED, McDougal JS, Ramsey RB. 1985. Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 312: 483-486.
72. Fischer B, Rehm J, Kirst M, Casas M, Hall W, Krausz M, Metrebian N, Reggers J, Uchtenhagen A, van den Brink W, et al. 2002. Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health 12: 228-234.
73. Fogel J, Hoover DR, Sun J, Mofenson LM, Fowler MG, Taylor AW, Kumwenda N, Taha TE, Eshleman SH. 2011a. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS 25: 911-917.
74. Fogel J, Li Q, Taha TE, Hoover DR, Kumwenda NI, Mofenson LM, Kumwenda JJ, Fowler MG, Thigpen MC, Eshleman SH. 2011b. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 52: 1069-1076.
75. Fowler MG, Lampe MA, Jamieson DJ, Kourtis AP, Rogers MF. 2007. Reducing the risk of mother-to-child human immunodeficiency virus transmission: Past successes, current progress and challenges, and future directions. Am J Obstet Gynecol 197: S3-S9.
76. Fowler MG, Gable AR, Lampe MA, Etima M, Owor M. 2010. Perinatal HIV and its prevention: Progress toward an HIV-free generation. Clin Perinatol 37: 699-719, vii.
77. Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S. 2010. Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS 24: 2397-2401.
78. Fritz K, McFarland W, Wyrod R, Chasakara C, Makumbe K, Chirowodza A, Mashoko C, Kellogg T, Woelk G. 2011. Evaluation of a peer network-based sexual risk reduction intervention for men in beer halls in Zimbabwe: Results from a randomized controlled trial. AIDS Behav. doi: 10. 1007/s10461-011-9922-1.
79. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. 2000. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection. J Virol 74: 6262-6268.
80. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci 102: 18514-18519.
81. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, et al. 2008. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5: e28. doi: 10. 1371/journal. pmed. 0050028.
82. Gazzard B, Clumeck N, d'Arminio Monforte A, Lundgren JD. 2008. Indicator disease-guided testing for HIV-The next step for Europe? HIV Med 9 Suppl 2: 34-40.
83. Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. 2007. The emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad Sci 104: 18566-18570.
84. Goldenberg RL, Stringer JS, Sinkala M, Vermund SH. 2002. Perinatal HIV transmission: Developing country considerations. J Matern Fetal Neonatal Med 12: 149-158.
85. Goldenberg RL, Mudenda V, Read JS, Brown ER, Sinkala M, Kamiza S, MartinsonF, Kaaya E, Hoffman I, Fawzi W, et al. 2006a. HPTN 024 study: Histologic chorioamnionitis, antibiotics and adverse infant outcomes in a predominantly HIV-1-infected African population. Am J Obstet Gynecol 195: 1065-1074.
86. Goldenberg RL, Mwatha A, Read JS, Adeniyi-Jones S, Sinkala M, Msmanga G, Martinson F, Hoffman I, Fawzi W, Valentine M, et al. 2006b. The HPTN 024 Study: The efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol 194: 650-661.
87. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A. 1981. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med 305: 1425-1431.
88. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
89. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, et al. 2007. Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 369: 657-666.
90. Gregson S, Nyamukapa CA, Garnett GP, Mason PR, Zhuwau T, Carael M, Chandiwana SK, Anderson RM. 2002. Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. Lancet 359: 1896-1903.
91. Hagan H, Perlman DC, Des Jarlais DC. 2011. Sexual risk and HIV infection among drug users in New York City: A pilot study. Subst Use Misuse 46: 201-207.
92. Hahn JA, Samet JH. 2010. Alcohol and HIV disease progression: Weighing the evidence. Curr HIV/AIDS Rep 7: 226-233.
93. Hallett TB, Gregson S, Lewis JJ, Lopman BA, Garnett GP. 2007. Behaviour change in generalised HIV epidemics: impact of reducing cross-generational sex and delaying age at sexual debut. Sex Transm Infect 83 (Suppl 1): i50-i54.
94. Hamers FF, Batter V, Downs AM, Alix J, Cazein F, Brunet JB. 1997. The HIV epidemic associated with injecting drug use in Europe: Geographic and time trends. AIDS 11: 1365-1374.
95. Hao C, Yan H, Yang H, Huan X, Guan W, Xu X, Zhang M, Tang W, Wang N, Gu J, et al. 2011. The incidence of syphilis, HIV and HCV and associated factors in a cohort of men who have sex with men in Nanjing, China. Sex Transm Infect 87: 199-201.
96. Harshbarger C, Simmons G, Coelho H, Sloop K, Collins C. 2006. An empirical assessment of implementation, adaptation, and tailoring: The evaluation of CDC's National Diffusion of VOICES/VOCES. AIDS Educ Prev 18: 184-197.
97. Heimer R. 2008. Community coverage and HIV prevention: Assessing metrics for estimating HIV incidence through syringe exchange. Int J Drug Policy 19(Suppl 1): S65-S73.
98. Helleringer S, Kohler HP. 2007. Sexual network structure and the spread of HIV in Africa: Evidence from Likoma Island, Malawi. AIDS 21: 2323-2332.
99. Hersh BS, Popovici F, Apetrei RC, Zolotusca L, Beldescu N, Calomfirescu A, Jezek Z, Oxtoby MJ, Gromyko A, Heymann DL. 1991a. Acquired immunodeficiency syndrome in Romania. Lancet 338: 645-649.
100. Hersh BS, Popovici F, Zolotusca L, Beldescu N, Oxtoby MJ, Gayle HD. 1991b. The epidemiology of HIV and AIDS in Romania. AIDS 5 (Suppl 2): S87-S92.
101. Holmes EC, Zhang LQ, Robertson P, Cleland A, Harvey E, Simmonds P, Leigh Brown AJ. 1995. The molecular epidemiology of human immunodeficiency virus type 1 in Edinburgh. J Infect Dis 171: 45-53.
102. Hue S, Pillay D, Clewley JP, Pybus OG. 2005. Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. Proc Natl Acad Sci 102: 4425-4429.
103. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. 2009. Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog 5: e1000590. doi: 10. 1371/journal. ppat. 1000590.
104. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. 2003. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43: 721-729.
105. Jamieson DJ, Clark J, Kourtis AP, Taylor AW, Lampe MA, Fowler MG, MofensonLM. 2007. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J Obstet Gynecol 197: S26-S32.
106. Johnson CV, Mimiaga MJ, Bradford J. 2008. Health care issues among lesbian, gay, bisexual, transgender and intersex (LGBTI) populations in the United States: Introduction. J Homosex 54: 213-224.
107. Jones JH, Handcock MS. 2003. An assessment of preferential attachment as a mechanism for human sexual network formation. Proc Biol Sci 270: 1123-1128.
108. Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. Int J Drug Policy 21: 335-342.
109. Kalish ML, Robbins KE, Pieniazek D, Schaefer A, Nzilambi N, Quinn TC, St Louis ME, Youngpairoj AS, Phillips J, Jaffe HW, et al. 2004. Recombinant viruses and early global HIV-1 epidemic. Emerg Infect Dis 10: 1227-1234.
110. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. 1999. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: Model-based regional estimates. Bull World Health Organ 77: 801-807.
111. Katz I, Low-Beer D. 2008. Why has HIV stabilized in South Africa, yet not declined further? Age and sexual behavior patterns among youth. Sex Transm Dis 35: 837-842.
112. Keeling MJ, Eames KT. 2005. Networks and epidemic models. J R Soc Interface 2: 295-307.
113. Khan MR, Bolyard M, Sandoval M, Mateu-Gelabert P, Krauss B, Aral SO, Friedman SR. 2009. Social and behavioral correlates of sexually transmitted infection-and HIV-discordant sexual partnerships in Bushwick, Brooklyn, New York. J Acquir Immune Defic Syndr 51: 470-485.
114. Kilmarx PH. 2009. Global epidemiology of HIV. Curr Opin HIV AIDS 4: 240-246.
115. Koblin BA, Chesney MA, Husnik MJ, Bozeman S, Celum CL, Buchbinder S, MayerK, McKirnan D, Judson FN, Huang Y, et al. 2003. High-risk behaviors among men who have sex with men in 6 US cities: Baseline data from the EXPLORE Study. Am J Public Health 93: 926-932.
116. Koblin B, Chesney M, Coates T. 2004. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: The EXPLORE randomised controlled study. Lancet 364: 41-50.
117. Kohler PK, Manhart LE, Lafferty WE. 2008. Abstinence-only and comprehensive sex education and the initiation of sexual activity and teen pregnancy. J Adolesc Health 42: 344-351.
118. Konde-Lule JK, Sewankambo N, Morris M. 1997. Adolescent sexual networking and HIV transmission in rural Uganda. Health Transit Rev 7 (Suppl): 89-100.
119. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, WolinskyS, Bhattacharya T. 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288: 1789-1796.
120. Kouyos RD, von W, Yerly S, Boni J, Taffe P, Shah C, Burgisser P, Klimkait T, Weber R, Hirschel B, et al. 2010. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 201: 1488-1497.
121. Kramer MA, van Veen MG, de Coul EL, Geskus RB, Coutinho RA, van de Laar MJ, Prins M. 2008. Migrants travelling to their country of origin: A bridge population for HIV transmission? Sex Transm Infect 84: 554-555.
122. Krupitsky E, Woody GE, Zvartau E, O'Brien CP. 2010. Addiction treatment in Russia. Lancet 376: 1145.
123. Kuiken CL, Goudsmit J. 1994. Silent mutation pattern in V3 sequences distinguishes virus according to risk group in Europe. AIDS Res Hum Retroviruses 10: 319-320.
124. Kuiken CL, Cornelissen MT, Zorgdrager F, Hartman S, Gibbs AJ, Goudsmit J. 1996. Consistent risk group-associated differences in human immunodeficiency virus type 1 vpr, vpu and V3 sequences despite independent evolution. J Gen Virol 77 (Pt 4): 783-792.
125. Kuiken C, Foley B, Leitner T, Apetrei RC, Hahn BH, Mizrachi I, Mullins JI, Rambaut A, Wolinsky S, Korber B, ed. 2010. HIV Sequence Compendium 2010. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM.
126. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. 2011. Combination HIV prevention: Significance, challenges, and opportunities. Curr HIV/AIDS Rep 8: 62-72.
127. Kwon JA, Iversen J, Maher L, Law MG, Wilson DP. 2009. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: A model-based analysis. J Acquir Immune Defic Syndr 51: 462-469.
128. Lackner AA, Lederman MM, Rodriguez B. 2011. HIV pathogenesis-The host. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a007005.
129. Lampe MA, Nesheim S, Shouse RL, Borkowf CB, Minasandram V, Little K, Kilmarx PH, Whitmore S, Taylor A, Valleroy L. 2010. Racial/ethnic disparities among children with diagnoses of perinatal HIV infection-34 states, 2004-2007. MMWR Morb Mortal Wkly Rep 59: 97-101.
130. Lansky A, Brooks JT, DiNenno E, Heffelfinger J, Hall HI, Mermin J. 2010. Epidemiology of HIV in the United States. J Acquir Immune Defic Syndr 55 Suppl 2: S64-S68.
131. Latora V, Nyamba A, Simpore J, Sylvette B, Diane S, Sylvere B, Musumeci S. 2006. Network of sexual contacts and sexually transmitted HIV infection in Burkina Faso. J Med Virol 78: 724-729.
132. Leigh Brown AJ. 1997. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci 94: 1862-1865.
133. Leigh Brown AJ, Richman DD. 1997. HIV-1: Gambling on the evolution of drug resistance? Nat Med 3: 268-271.
134. Leigh Brown AJ, Lobidel D, Wade CM, Rebus S, Phillips AN, Brettle RP, FranceAJ, Leen CS, McMenamin J, McMillan A, et al. 1997. The molecular epidemiology of human immunodeficiency virus type 1 in six cities in Britain and Ireland. Virology 235: 166-177.
135. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ. 2003. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187: 683-686.
136. Leigh Brown AJ, Lycett SJ, Weinert L, Hughes GJ, Fearnhill E, Dunn DT. UK HIV Drug Resistance Collaboration. 2011. Transmission network parameters estimated from HIV sequences for a nation-wide epidemic. J Infect Dis (in press).
137. Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme AM. 2003. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci 100: 6588-6592.
138. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ. 2008. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med 5: e50. doi: 10. 1371/journal. pmed. 0050050.
139. Liitsola K, Tashkinova I, Laukkanen T, Korovina G, Smolskaja T, Momot O, Mashkilleyson N, Chaplinskas S, Brummer-Korvenkontio H, Vanhatalo J, et al. 1998. HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. AIDS 12: 1907-1919.
140. Liitsola K, Holm K, Bobkov A, Pokrovsky V, Smolskaya T, Leinikki P, OsmanovS, Salminen M. 2000. An AB recombinant and its parental HIV type 1 strains in the area of the former Soviet Union: Low requirements for sequence identity in recombination. UNAIDS Virus Isolation Network. AIDS Res Hum Retroviruses 16: 1047-1053.
141. Lindegren ML, Byers RH Jr., Thomas P, Davis SF, Caldwell B, Rogers M, GwinnM, Ward JW, Fleming PL. 1999. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 282: 531-538.
142. Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, HellmannNS, Petropoulos CJ, Sutton L, Pitt JA, et al. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282: 1142-1149.
143. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, MellorsJW, Connick E, Conway B, et al. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385-394.
144. Lukashov VV, Kuiken CL, Vlahov D, Coutinho RA, Goudsmit J. 1996. Evidence for HIV type 1 strains of U. S. intravenous drug users as founders of AIDS epidemic among intravenous drug users in northern Europe. AIDS Res Hum Retroviruses 12: 1179-1183.
145. Lurie P, Drucker E. 1997. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 349: 604-608.
146. Lyles CM, Crepaz N, Herbst JH, Kay LS. 2006. Evidence-based HIV behavioral prevention from the perspective of the CDC's HIV/AIDS Prevention Research Synthesis Team. AIDS Educ Prev 18: 21-31.
147. Mah TL, Halperin DT. 2010. Concurrent sexual partnerships and the HIV epidemics in Africa: Evidence to move forward. AIDS Behav 14: 11-16; dicussion 34-17.
148. Mahajan AP, Sayles JN, Patel VA, Remien RH, Sawires SR, Ortiz DJ, Szekeres G, Coates TJ. 2008. Stigma in the HIV/AIDS epidemic: A review of the literature and recommendations for the way forward. AIDS 22 Suppl 2: S67-S79.
149. Mahy M, Warner-Smith M, Stanecki KA, Ghys PD. 2009. Measuring the impact of the global response to the AIDS epidemic: Challenges and future directions. J Acquir Immune Defic Syndr 52 Suppl 2: S152-S159.
150. Malebranche DJ. 2008. Bisexually active Black men in the United States and HIV: Acknowledging more than the "down low". Arch Sex Behav 37: 810-816.
151. Margaret Dolcini M, Gandelman AA, Vogan SA, Kong C, Leak TN, King AJ, Desantis L, O'Leary A. 2010. Translating HIV interventions into practice: Community-based organizations' experiences with the diffusion of effective behavioral interventions (DEBIs). Soc Sci Med 71: 1839-1846.
152. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A, Strathdee SA. 2010. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet 375: 1014-1028.
153. McDonald AM, Zurynski YA, Wand HC, Giles ML, Elliott EJ, Ziegler JB, Kaldor JM. 2009. Perinatal exposure to HIV among children born in Australia, 1982-2006. Med J Aust 190: 416-420.
154. McGowan I. 2011. Rectal microbicides: Can we make them and will people use them? AIDS Behav 15 (Suppl 1): S66-S71.
155. Mercer CH, Copas AJ, Sonnenberg P, Johnson AM, McManus S, Erens B, CassellJA. 2009. Who has sex with whom? Characteristics of heterosexual partnerships reported in a national probability survey and implications for STI risk. Int J Epidemiol 38: 206-214.
156. Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, Morfeldt-Manson L, Asjo B, Wain-Hobson S. 1989. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 58: 901-910.
157. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. 2008. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: A meta-analysis. JAMA 300: 1674-1684.
158. Millett GA, Crowley JS, Koh H, Valdiserri RO, Frieden T, Dieffenbach CW, Fenton KA, Benjamin R, Whitescarver J, Mermin J, et al. 2010. A way forward: The National HIV/AIDS Strategy and reducing HIV incidence in the United States. J Acquir Immune Defic Syndr 55 Suppl 2: S144-S147.
159. Mills E, Cooper C, Anema A, Guyatt G. 2008. Male circumcision for the prevention of heterosexually acquired HIV infection: A meta-analysis of randomized trials involving 11, 050 men. HIV Med 9: 332-335.
160. Mofenson LM. 2003. Advances in the prevention of vertical transmission of human immunodeficiency virus. Semin Pediatr Infect Dis 14: 295-308.
161. Mofenson LM. 2010. Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 15: 537-553.
162. Mofenson LM, Fowler MG. 1999. Interruption of materno-fetal transmission. AIDS 13 (Suppl A): S205-S214.
163. Mofenson LM, McIntyre JA. 2000. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 355: 2237-2244.
164. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, Thior I, Wester C, Wester CW, Ogwu A, et al. 2010. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS One 5: e10148. doi: 10. 1371/journal. pone. 0010148.
165. Op de Coul EL, Prins M, Cornelissen M, van der Schoot A, Boufassa F, BrettleRP, Hernandez-Aguado L, Schiffer V, McMenamin J, Rezza G, et al. 2001. Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997. AIDS 15: 257-266.
166. Ott MA, Santelli JS. 2007. Abstinence and abstinence-only education. Curr Opin Obstet Gynecol 19: 446-452.
167. Ou CY, Takebe Y, Weniger BG, Luo CC, Kalish ML, Auwanit W, Yamazaki S, Gayle HD, Young NL, Schochetman G. 1993. Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet 341: 1171-1174.
168. Overbaugh J, Morris L. 2011. The antibody response against HIV-1. Cold Spring Harbor Perspect Med doi: 10. 1101/cshperspect. a007039.
169. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. 2010. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews. Addiction 105: 844-859.
170. Pape J, Johnson WD Jr. 1993. AIDS in Haiti 1982-1992. Clin Infect Dis 17(Suppl 2): S341-S345.
171. Parry JV, Murphy G, Barlow KL, Lewis K, Rogers PA, Belda FJ, Nicoll A, McGarrigle C, Cliffe S, Mortimer PP, et al. 2001. National surveillance of HIV-1 subtypes for England and Wales: Design, methods, and initial findings. J Acquir Immune Defic Syndr 26: 381-388.
172. Parry CD, Carney T, Petersen P, Dewing S, Needle R. 2009. HIV-risk behavior among injecting or non-injecting drug users in Cape Town, Pretoria, and Durban, South Africa. Subst Use Misuse 44: 886-904.
173. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551-1557.
174. Perrin L, Yerly S, Rakik A, Kinloch S, Hirschel B. 1994. Transmission of 215 mutants in primary HIV infection and analysis after 6 months of zidovudine. AIDS 8: pS3.
175. Peters VB, Liu KL, Robinson LG, Dominguez KL, Abrams EJ, Gill BS, Thomas PA. 2008. Trends in perinatal HIV prevention in New York City, 1994-2003. Am J Public Health 98: 1857-1864.
176. Pickering H, Okongo M, Ojwiya A, Yirrell D, Whitworth J. 1997. Sexual networks in Uganda: Mixing patterns between a trading town, its rural hinterland and a nearby fishing village. Int J STD AIDS 8: 495-500.
177. Pinching AJ. 1984. The acquired immune deficiency syndrome. Clin Exp Immunol 56: 1-13.
178. Powers KA, Poole C, Pettifor AE, Cohen MS. 2008. Rethinking the heterosexual infectivity of HIV-1: A systematic review and meta-analysis. Lancet Infect Dis 8: 553-563.
179. Qian HZ, Stinnette SE, Rebeiro PF, Kipp AM, Shepherd BE, Samenow CP, JenkinsCA, No P, McGowan CC, Hulgan T, et al. 2011. The relationship between injection and noninjection drug use and HIV disease progression. J Subst Abuse Treat 41: 14-20.
180. Quigg M, Rebus S, France AJ, McMenamin J, Darby G, Leigh Brown AJ. 1997. Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors. AIDS 11: 835-836.
181. Rambaut A, Robertson DL, Pybus OG, Peeters M, Holmes EC. 2001. Human immunodeficiency virus. Phylogeny and the origin of HIV-1. Nature 410: 1047-1048.
182. Rambaut A, Posada D, Crandall KA, Holmes EC. 2004. The causes and consequences of HIV evolution. Nat Rev Genet 5: 52-61.
183. Read JS. 2010. Prevention of mother-to-child transmission of HIV: Antiretroviral strategies. Clin Perinatol 37: 765-776, viii.
184. Reithinger R, Megazzini K, Durako SJ, Harris DR, Vermund SH. 2007. Monitoring and evaluation of programmes to prevent mother to child transmission of HIV in Africa. BMJ 334: 1143-1146.
185. Remien RH, Mellins CA. 2007. Long-term psychosocial challenges for people living with HIV: Let's not forget the individual in our global response to the pandemic. AIDS 21 (Suppl 5): S55-S63.
186. Resik S, Lemey P, Ping LH, Kouri V, Joanes J, Perez J, Vandamme AM, Swanstrom R. 2007. Limitations to contact tracing and phylogenetic analysis in establishing HIV type 1 transmission networks in Cuba. AIDS Res Hum Retroviruses 23: 347-356.
187. Reynolds SJ, Quinn TC. 2010. Setting the stage: Current state of affairs and major challenges. Clin Infect Dis 50 (Suppl 3): S71-S76.
188. Rietmeijer CA, Patnaik JL, Judson FN, Douglas JM Jr. 2003. Increases in gonorrhea and sexual risk behaviors among men who have sex with men: A 12-year trend analysis at the Denver Metro Health Clinic. Sex Transm Dis 30: 562-567.
189. Robbins KE, Lemey P, Pybus OG, Jaffe HW, Youngpairoj AS, Brown TM, SalemiM, Vandamme AM, Kalish ML. 2003. U. S. human immunodeficiency virus type 1 epidemic: Date of origin, population history, and characterization of early strains. J Virol 77: 6359-6366.
190. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, et al. 2000. HIV-1 nomenclature proposal. Science 288: 55-56.
191. Rosenthal E. 2006. HIV injustice in Libya-Scapegoating foreign medical professionals. N Engl J Med 355: 2505-2508.
192. Rothenberg R. 2009. HIV transmission networks. Curr Opin HIV AIDS 4: 260-265.
193. Rotheram-Borus MJ, Swendeman D, Chovnick G. 2009. The past, present, and future of HIV prevention: Integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 5: 143-167.
194. Sahasrabuddhe VV, Vermund SH. 2007. The future of HIV prevention: Control of sexually transmitted infections and circumcision interventions. Infect Dis Clin North Am 21: 241-257, xi.
195. Salemi M, de Oliveira T, Ciccozzi M, Rezza G, Goodenow MM. 2008. High-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania. PLoS One 3: e1390. doi: 10. 1371/journal. pone. 0001390.
196. Salomon EA, Mimiaga MJ, Husnik MJ, Welles SL, Manseau MW, Montenegro AB, Safren SA, Koblin BA, Chesney MA, Mayer KH. 2009. Depressive symptoms, utilization of mental health care, substance use and sexual risk among young men who have sex with men in EXPLORE: Implications for age-specific interventions. AIDS Behav 13: 811-821.
197. Sambrook J, Sleigh M, Engler JA, Broker TR. 1980. The evolution of the adenoviral genome. Ann NY Acad Sci 354: 426-452.
198. Samet JH, Walley AY, Bridden C. 2007. Illicit drugs, alcohol, and addiction in human immunodeficiency virus. Panminerva Med 49: 67-77.
199. Sarang A, Stuikyte R, Bykov R. 2007. Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy 18: 129-135.
200. Sarang A, Rhodes T, Platt L. 2008. Access to syringes in three Russian cities: Implications for syringe distribution and coverage. Int J Drug Policy 19 (Suppl 1): S25-S36.
201. Scheer S, Kellogg T, Klausner JD, Schwarcz S, Colfax G, Bernstein K, Louie B, Dilley JW, Hecht J, Truong HM, et al. 2008. HIV is hyperendemic among men who have sex with men in San Francisco: 10-year trends in HIV incidence, HIV prevalence, sexually transmitted infections and sexual risk behaviour. Sex Transm Infect 84: 493-498.
202. Selik RM, Haverkos HW, Curran JW. 1984. Acquired immune deficiency syndrome (AIDS) trends in the United States, 1978-1982. Am J Med 76: 493-500.
203. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspec Med doi: 10. 1101/cshperspect. a006841.
204. Shaw SJ. 2006. Public citizens, marginalized communities: The struggle for syringe exchange in Springfield, Massachusetts. Med Anthropol 25: 31-63.
205. Shaw GM, Hunter E. 2011. HIV transmission. Cold Spring Harb Perspect Med doi: 10. 1011/cshperspect. a006965.
206. Siegfried N, Muller M, Deeks JJ, Volmink J. 2009. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev CD003362.
207. Sikora C, Chandran AU, Joffe AM, Johnson D, Johnson M. 2010. Population risk of syringe reuse: Estimating the probability of transmitting bloodborne disease. Infect Control Hosp Epidemiol 31: 748-754.
208. Simon F, Loussert-Ajaka I, Damond F, Saragosti S, Barin F, Brun-Vezinet F. 1996. HIV type 1 diversity in northern Paris, France. AIDS Res Hum Retroviruses 12: 1427-1433.
209. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. 1999. Unsafe injections in the developing world and transmission of bloodborne pathogens: A review. Bull World Health Organ 77: 789-800.
210. Steffenson AE, Pettifor AE, Seage GR 3rd., Rees HV, Cleary PD. 2011. Concurrent sexual partnerships and human immunodeficiency virus risk among South African youth. Sex Transm Dis. 38: 459-466.
211. Strauss SM, Rindskopf DM. 2009. Screening patients in busy hospital-based HIV care centers for hazardous and harmful drinking patterns: The identification of an optimal screening tool. J Int Assoc Physicians AIDS Care (Chic) 8: 347-353.
212. Strauss SM, Tiburcio NJ, Munoz-Plaza C, Gwadz M, Lunievicz J, Osborne A, Padilla D, McCarty-Arias M, Norman R. 2009. HIV care providers' implementation of routine alcohol reduction support for their patients. AIDS Patient Care STDS23: 211-218.
213. Stringer JS, Vermund SH. 1999. Prevention of mother-to-child transmission of HIV-1. Curr Opin Obstet Gynecol 11: 427-434.
214. Stringer JS, Sinkala M, Maclean CC, Levy J, Kankasa C, Degroot A, Stringer EM, Acosta EP, Goldenberg RL, Vermund SH. 2005. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS19: 1309-1315.
215. Stringer EM, Chi BH, Chintu N, Creek TL, Ekouevi DK, Coetzee D, Tih P, BoulleA, Dabis F, Shaffer N, et al. 2008. Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries. Bull World Health Organ 86: 57-62.
216. Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K, Giganti MJ, Welty TK, Chintu N, Chi BH, et al. 2010. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA 304: 293-302.
217. Swanstrom R, Coffin J. 2011. HIV-1 pathogenesis: The virus. Cold Spring Harb Perspect Biol. doi: 10. 1101/cshperspect. a007443.
218. Taha TE, Brown ER, Hoffman IF, Fawzi W, Read JS, Sinkala M, Martinson FE, Kafulafula G, Msamanga G, Emel L, et al. 2006. A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS 20: 1313-1321.
219. Tempalski B, Flom PL, Friedman SR, Des Jarlais DC, Friedman JJ, McKnight C, Friedman R. 2007. Social and political factors predicting the presence of syringe exchange programs in 96 US metropolitan areas. Am J Public Health 97: 437-447.
220. Thomson MM, Perez-Alvarez L, Najera R. 2002. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2: 461-471.
221. Toussova O, Shcherbakova I, Volkova G, Niccolai L, Heimer R, Kozlov A. 2009. Potential bridges of heterosexual HIV transmission from drug users to the general population in St. Petersburg, Russia: Is it easy to be a young female? J Urban Health 86 (Suppl 1): 121-130.
222. Trenholm C, Devaney B, Fortson K, Clark M, Bridgespan LQ, Wheeler J. 2008. Impacts of abstinence education on teen sexual activity, risk of pregnancy, and risk of sexually transmitted diseases. J Policy Anal Manage 27: 255-276.
223. van Griensven F, de Lind van Wijngaarden JW. 2010. A review of the epidemiology of HIV infection and prevention responses among MSM in Asia. AIDS 24 (Suppl 3): S30-S40.
224. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kucherer C, Struck D, Schmit JC, Asjo B, et al. 2009. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200: 1503-1508.
225. Vermund SH, Allen KL, Karim QA. 2009. HIV-prevention science at a crossroads: Advances in reducing sexual risk. Curr Opin HIV AIDS 4: 266-273.
226. Vermund SH, Hodder SL, Justman JE, Koblin BA, Mastro TD, Mayer KH, WheelerDP, El-Sadr WM. 2010. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis 50 Suppl 3: S149-155.
227. Vermund SH, Qian HZ. 2008. Circumcision and HIV prevention among men who have sex with men: No final word. JAMA 300: 1698-1700.
228. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. 2007. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev CD003510.
229. Volz EM, Kosakovsky Pond SL, Ward MJ, Leigh Brown AJ, Frost SD. 2009. Phylodynamics of infectious disease epidemics. Genetics 183: 1421-1430.
230. Wade NA, Zielinski MA, Butsashvili M, McNutt LA, Warren BL, Glaros R, ChekuB, Pulver W, Pass K, Fox K, et al. 2004. Decline in perinatal HIV transmission in New York State (1997-2000). J Acquir Immune Defic Syndr 36: 1075-1082.
231. Walker B, McMichael A. 2011. The T-cell response to HIV. Cold Spring Harbor Perspect Med doi: 10. 1101/cshperspect. a007054.
232. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr., LaLota M, Dickinson G, Schwarcz S, Torian L, et al. 2004. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189: 2174-2180.
233. Weiss HA, Quigley MA, Hayes RJ. 2000. Male circumcision and risk of HIV infection in sub-Saharan Africa: A systematic review and meta-analysis. AIDS14: 2361-2370.
234. Weiss HA, Dickson KE, Agot K, Hankins CA. 2010. Male circumcision for HIV prevention: Current research and programmatic issues. AIDS 24 (Suppl 4): S61-S69.
235. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, et al. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 192: 958-966.
236. Whitmore SK, Patel-Larson A, Espinoza L, Ruffo NM, Rao S. 2010. Missed opportunities to prevent perinatal human immunodeficiency virus transmission in 15 jurisdictions in the United States during 2005-2008. Women Health 50: 414-425.
237. Whitmore SK, Zhang X, Taylor AW, Blair JM. 2011. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr. 57: 218-222.
238. Williamson C, Shao Y. 2011. The HIV epidemic: Low-to middle-income countries. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a007187.
239. Wingood GM, DiClemente RJ. 2006. Enhancing adoption of evidence-based HIV interventions: Promotion of a suite of HIV prevention interventions for African American women. AIDS Educ Prev 18: 161-170.
240. Wolfe D, Carrieri MP, Shepard D. 2010. Treatment and care for injecting drug users with HIV infection: A review of barriers and ways forward. Lancet 376: 355-366.
241. Wolfs TF, de Jong JJ, Van den Berg H, Tijnagel JM, Krone WJ, Goudsmit J. 1990. Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci 87: 9938-9942.
242. Wolitski RJ, Valdiserri RO, Denning PH, Levine WC. 2001. Are we headed for a resurgence of the HIV epidemic among men who have sex with men? Am J Public Health 91: 883-888.
243. Xu JJ, Zhang M, Brown K, Reilly K, Wang H, Hu Q, Ding H, Chu Z, Bice T, ShangH. 2010. Syphilis and HIV seroconversion among a 12-month prospective cohort of men who have sex with men in Shenyang, China. Sex Transm Dis 37: 432-439.
244. Yang Q, Boulos D, Yan P, Zhang F, Remis RS, Schanzer D, Archibald CP. 2010. Estimates of the number of prevalent and incident human immunodeficiency virus (HIV) infections in Canada, 2008. Can J Public Health 101: 486-490.
245. Yerly S, Junier T, Gayet-Ageron A, Amari EB, von Wyl V, Gunthard HF, HirschelB, Zdobnov E, Kaiser L. 2009. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 23: 1415-1423.
246. Yirrell DL, Pickering H, Palmarini G, Hamilton L, Rutemberwa A, Biryahwaho B, Whitworth J, Brown AJ. 1998. Molecular epidemiological analysis of HIV in sexual networks in Uganda. AIDS 12: 285-290.
247. Zetterberg V, Ustina V, Liitsola K, Zilmer K, Kalikova N, Sevastianova K, Brummer-Korvenkontio H, Leinikki P, Salminen MO. 2004. Two viral strains and a possible novel recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in Estonia. AIDS Res Hum Retroviruses 20: 1148-1156.